Analysis of variables and interactions among variables associated with a sustained virological response to pegylated interferon alfa-2a plus ribavirin in hepatitis C virus genotype 3-infected patients

International Journal of Infectious Diseases

Volumn 16, Issue 8, 2012, Pages

  Aziz, Hafsa ^a   Raza, Abida ^a   Waheed, Yasir ^b   Gill, Uzma ^c   Gill, Muzaffar Lateef ^c  

^a PAKISTAN ATOMIC ENERGY COMMISSION   (Pakistan)

^b NATIONAL UNIVERSITY OF SCIENCES AND TECHNOLOGY   (Pakistan)

^c Islamabad Specialist Clinic   (Pakistan)

Author keywords

HCV; HCV genotype 3; Pegylated interferon

Indexed keywords

PEGINTERFERON ALPHA2A; RIBAVIRIN;

ADULT; AGE; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALOPECIA; ANEMIA; ARTICLE; BODY MASS; CHRONIC HEPATITIS; CLINICAL EFFECTIVENESS; COUGHING; DECREASED APPETITE; DEPRESSION; DRUG EFFICACY; FATIGUE; FEMALE; FEVER; GENDER; GENOTYPE; HEADACHE; HEPATITIS C; HUMAN; INSOMNIA; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; MYALGIA; NAUSEA; OUTCOME ASSESSMENT; RAPID VIROLOGICAL RESPONSE; SUSTAINED VIROLOGICAL RESPONSE; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; UNIVARIATE ANALYSIS; VIRAL CLEARANCE; VIRUS LOAD;

ADULT; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; PROGNOSIS; PROSPECTIVE STUDIES; RECOMBINANT PROTEINS; RIBAVIRIN; TREATMENT OUTCOME; VIRAL LOAD; YOUNG ADULT;

EID: 84864395603     PISSN: 12019712     EISSN: 18783511     Source Type: Journal    
DOI: 10.1016/j.ijid.2012.03.012     Document Type: Article

References (30)

1. Wands J.R. Prevention of hepatocellular carcinoma. N Engl J Med 2004, 351:1567-1570.
2. World Health Organization Epidemic and pandemic alert and response (EPR) for HCV 2002, WHO, Geneva, Available at: http://www.who.int/csr/disease/hepatitis/whocdscsrlyo2003/en/index4.html (accessed May 2011).
3. McCaughan G.W., Omata M., Amarapurkar D., Bowden S., Chow W.C., Chutaputti A., et al. Asian Pacific Association for the Study of the Liver (APASL) Hepatitis C Working Party. Asian Pacific Association for the Study of the Liver consensus statements on the diagnosis, management and treatment of hepatitis C virus infection. J Gastroenterol Hepatol 2007, 22:615-633.
4. Aziz H., Athar M.A., Murtaza S., Irfan J., Waheed Y., Bilal I., Raza A. Predictors of response to antiviral therapy in patients with chronic hepatitis C from Pakistani population. Chin Med J (Engl) 2011, 124:1333-1337.
5. Perz J.F., Armstrong G.L., Farrington L.A., Hutin Y.J., Bell B.P. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 2006, 45:529-538.
6. Saito I., Miyamura T., Ohbayashi A., Harada H., Katayama T., Kikuchi S., et al. Hepatitis C virus infection is associated with the development of hepatocellular carcinoma. Proc Natl Acad Sci U S A 1990, 87:6547-6549.
7. Strader D.B., Wright T., Thomas D.L., Seeff L.B. Diagnosis, management, and treatment of hepatitis C. Hepatology 2004, 39:1147-1171.
8. Attaullah S., Khan S., Ali I. Hepatitis C virus genotypes in Pakistan: a systemic review. Virol J 2011, 8:433.
9. Hadziyannis S.J., Sette H., Morgan T.R., Balan V., Diago M., Marcellin P., et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004, 140:346-355. PEGASYS International Study Group.
10. Khokhar N., Butt M.B., Gill M.L. Successful treatment of resistant chronic hepatitis C virus infection with high dose pegylated interferon. J Coll Phys Surg Pak 2005, 15:41-42.
11. Butt A.S., Mumtaz K., Aqeel I., Shah H.A., Hamid S., Jafri W. Sustained virological response to pegylated interferon and ribavirin in patients with HCV genotype 3 HCV cirrhosis. Trop Gastroenterol 2009, 30:207-212.
12. Aziz H., Gil M.L., Waheed Y., Adeeb U., Raza A., Bilal I., Athar M.A. Evaluation of prognostic factors for peg interferon alfa-2b plus ribavirin treatment on HCV infected patients in Pakistan. Infect Genet Evol 2011, 11:640-645.
13. Germer J.J., Majewski D.W., Yung M., Mitchell P.S., Yao J.D. Evaluation of the Invader assay for genotyping hepatitis C virus. J Clin Microbiol 2006, 44:318-323.
14. Dalgard O., Bjøro K., Hellum K.B., Myrvang B., Ritland S., Skaug K., et al. Treatment with pegylated interferon and ribavirin in HCV infection with genotype 2 or 3 for 14 weeks: a pilot study. Hepatology 2004, 40:1260-1265.
15. NIH Consensus Statement on Management of Hepatitis C: 2002. NIH Consens State Sci Statements 2002;19: 1-46.
16. Hu K.Q., Vierling J.M., Redeker A.G. Viral, host and interferon-related factors modulating the effect of interferon therapy for hepatitis C virus infection. J Viral Hepat 2001, 8:1-18.
17. Nadeem S.R., Khalid A.J. Epidemiology of hepatitis C infection in Pakistan. J Microbiol Immunol Infect 2008, 41:4-8.
18. Higuchi M., Tanaka E., Kiyosawa K. Epidemiology and clinical aspects on hepatitis C. Jpn J Infect Dis 2002, 55:69-77.
19. Ascione A., De Luca M., Tartaglione M.T., Lampasi F., DiCostanzo G.G., Lanza A.G., et al. Peginterferon alfa-2a plus ribavirin is more effective than peginterferon alfa-2b plus ribavirin for treating chronic hepatitis C virus infection. Gastroenterology 2010, 138:116-122.
20. Rumi M.G., Aghemo A., Prati G.M., D'Ambrosio R., Donato M.F., Soffredini R., et al. Randomized study of peginterferon-alpha2a plus ribavirin vs peginterferon-alpha2b plus ribavirin in chronic hepatitis C. Gastroenterology 2010, 138:108-115.
21. Puoti C., Barbarini G., Picardi A., Romano M., Pellicelli A., Barlattani A., et al. Rapid virological response as a predictor of sustained response in HCV-infected patients with persistently normal alanine aminotransferase levels: a multicenter study. J Viral Hepat 2011, 18:393-399.
22. Hayashi J., Kishihara Y., Ueno K., Yamaji K., Kawakami Y., Furusyo N., et al. Age related response to interferon alfa treatment in women vs men with chronic hepatitis C virus infection. Arch Intern Med 1998, 158:177-181.
23. Akram M., Idrees M., Zafar S., Hussain A., Butt S., Afzal S., et al. Effects of host and virus related factors on interferon-a+ribavirin and pegylated-interferon+ribavirin treatment outcomes in chronic hepatitis C patients. Virol J 2011, 8:234.
24. Xie Y., Xu D.Z., Lu Z.M., Luo K.X., Jia J.D., Wang Y.M., et al. Predictive factors for sustained response to interferon treatment in patients with chronic hepatitis C: a randomized, open, and multi-center controlled trial. Hepatobiliary Pancreat Dis Int 2005, 4:213-219.
25. Shin S.R., Sinn D.H., Gwak G.Y., Choi M.S., Lee J.H., Koh K.C., et al. Risk factors for relapse in chronic hepatitis C patients who have achieved end of treatment response. J Gastroenterol Hepatol 2010, 25:957-963.
26. Idrees M., Riazuddin S. A study of best positive predictors for sustained virologic response to interferon alpha plus ribavirin therapy in naive chronic hepatitis C patients. BMC Gastroenterol 2009, 9:5.
27. Lam N.P. Hepatitis C: natural history, diagnosis, and management. Am J Health Syst Pharm 1999, 56:961-973.
28. Davis G.L., Esteban-Mur R., Rustgi V., Hoefs J., Gordon S.C., Trepo C., et al. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. N Engl J Med 1998, 339:1493-1499.
29. Jensen D.M., Krawitt E.L., Keeffe E.B., Hollinger F.B., James S.P., Mullen K., et al. Biochemical and viral response to consensus interferon (CIFN) therapy in chronic hepatitis C patients: effect of baseline viral concentration. Am J Gastroenterol 1999, 94:3583-3585.
30. Rodriguez-Torres M., Sulkowski M.S., Chung R.T., Hamzeh F.M., Jensen D.M. Factors associated with rapid and early virologic response to peginterferon alfa2a/ribavirin treatment in HCV genotype 1 patients representative of the general chronic hepatitis C population. J Viral Hepat 2010, 17:139-147.